SCHEDULE: Ridgeback Capital Exits iTeos Therapeutics Stake

Ridgeback Capital Investments L.P. and its affiliates have reported divesting their entire beneficial ownership in iTeos Therapeutics, Inc., now holding 0.0% of common stock.

Summary

• Ridgeback Capital Investments L.P., Ridgeback Capital Investments LLC, and Ridgeback Capital Management LLC (collectively, the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13G.
• The Reporting Persons now beneficially own 0.0% of iTeos Therapeutics, Inc.'s common stock.
• This indicates a complete divestment of their previous stake, which was approximately 5.1% of shares outstanding as of August 1, 2025.
• The event date that triggered this amendment, signifying the change in ownership, was September 30, 2025.

Sentiment

Score: 3

Explanation: The complete divestment by a significant institutional investor is a negative signal for the company, indicating a loss of confidence or a strategic shift by the investor. While it's a regulatory filing and not a company announcement, the action itself is unfavorable for iTeos Therapeutics' stock.

Negatives

• A significant institutional investor, Ridgeback Capital, has fully divested its stake in iTeos Therapeutics, Inc.
• The previous beneficial ownership was approximately 5.1% of the class, indicating a complete exit from a substantial position.

Risks

• Loss of institutional investor support and potential downward pressure on share price due to the divestment.
• Reduced institutional ownership may impact market liquidity and investor sentiment for iTeos Therapeutics.

Future Outlook

The filing does not contain forward-looking statements or guidance from iTeos Therapeutics, Inc. It solely reports a change in beneficial ownership by an institutional investor.

Industry Context

The divestment by Ridgeback Capital, a significant institutional investor, could signal a re-evaluation of iTeos Therapeutics' prospects within the competitive biotechnology sector. Such exits can sometimes precede or follow significant company-specific news or broader shifts in investor sentiment towards a particular therapeutic area or company's pipeline.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure for a change in beneficial ownership. Without specific financial or operational results from iTeos Therapeutics, a direct comparison to industry benchmarks or comparable companies is not applicable based solely on this document.
• The divestment itself, however, could be compared to similar actions by institutional investors in other small-to-mid cap biotech firms, where changes in major shareholder positions can have a more pronounced impact on stock performance and investor confidence.

Stakeholder Impact

• Shareholders: Potential negative impact on share price due to the divestment and reduced institutional ownership.
• Company Management: May face questions regarding the reasons for the institutional investor's exit and its implications for future investor relations.

Next Steps

• The filing does not mention any specific future actions or milestones for iTeos Therapeutics. It is a disclosure of past ownership changes by an external entity.

Key Dates

Recommendation

The complete divestment by a significant institutional investor like Ridgeback Capital, which previously held over 5% of iTeos Therapeutics, signals a strong negative sentiment from a sophisticated market participant. This action suggests a lack of conviction in the company's future prospects or a re-evaluation of its risk-reward profile. Such a substantial exit typically puts downward pressure on the stock price and can erode broader investor confidence, making a 'sell' recommendation prudent for existing holders and advising against new positions until clearer positive catalysts emerge.

Keywords

iTeos Therapeutics, Ridgeback Capital, Schedule 13G, Beneficial Ownership, Divestment, Institutional Investor, Common Stock, Biotechnology, SEC Filing